Stay updated with breaking news from கேய்ட் ஃப்லெர்டீ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Many Pandemic-Driven Changes to Cancer CTs Should Remain medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
A well-funded cancer drug startup brings on GSK's Axel Hoos as CEO biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.
Bostonâs hospital chiefs moonlight on corporate boards at rates far beyond the national level Hospital chiefs and trustees defend this as boosting public-private partnerships, but critics say these board positions - some paying millions of dollars - raise troubling issues of conflict of interest and hospital priorities. By Liz Kowalczyk, Spotlight fellow Sarah L. Ryley, Mark Arsenault and Spotlight editor Patricia Wen Globe Staff and Globe Staff,Updated April 3, 2021, 4:54 p.m. Email to a Friend Globe Staff/Photo Illustration by Globe Staff As chief of Boston Childrenâs Hospital, one of the most esteemed pediatric hospitals in the world, Sandra Fenwick had outsized influence. After the pandemic struck last spring, she used that clout to lobby Massachusetts legislators for more money for telemedicine, a suddenly essential alternative to in-person visits. ....
E-Mail A test that monitors blood levels of DNA fragments released by dying tumor cells may serve as an accurate early indicator of treatment success in people in late stages of one of the most aggressive forms of skin cancer, a new study finds. Led by NYU Grossman School of Medicine and Perlmutter Cancer Center researchers, the investigation looked at adults with undetectable levels of freely circulating tumor DNA (ctDNA) four weeks into drug treatment for metastatic melanoma tumors that cannot be removed surgically (unresectable). The study showed that these patients, all of whom had common genetic changes (BRAFV600 mutations) linked to cancer, were living nearly twice as long without cancer growth as those who continued to have detectable levels. ....
With biotech funding at âall-time high,â Scorpion scoops up $162 million By Anissa Gardizy Globe Staff,Updated January 7, 2021, 7:00 a.m. Email to a Friend Just over two months after announcing its debut with $108 million in funding, Boston startup Scorpion Therapeutics said Thursday it has raised an even larger amount of venture capital. Scorpion, which focuses on âprecision medicineâ for cancer, said it has completed a $162 million funding round, bringing the biotechâs total venture haul to about $270 million. Itâs a large amount for a new company that so far has kept much of its work under wraps, and a sign that the regionâs early-stage biotech industry is vibrant, despite the pandemic. ....